Breaking Research News from sources other than Breastcancer.org
Comments
-
NIH Leader Shuns All-Male Panels. Many Applaud the Gesture, but Not All.
Francis Collins won't participate in those so-called manels anymore. Many scientists see that as a constructive move toward inclusiveness, but a critic calls the stance unscientific political theater.
https://www.chronicle.com/article/NIH-Leader-Shuns...
{Requires subscription. I will see if I can find a free report on same subject matter.}
0 -
The NIH director is tired of all-male panels at scientific conventions. So he's doing something about it
https://www.cnn.com/2019/06/13/us/nih-director-male-panels-trnd/index.html
N.I.H. Head Calls for End to All-Male Panels of Scientists
Francis Collins pledged to decline to speak at conferences that do not include enough women in prominent speaking roles.
https://www.nytimes.com/2019/06/12/health/collins-male-science-panels.html
{NYT generally allows a limited number of free accesses per month.}
0 -
Shame on the FDA, is there any agency we can trust?
Published 12 hours ago
Breast implants linked to rare form of cancer, but FDA declines to ban
https://www.foxnews.com/health/breast-implants-lin...0 -
I have thought about this many times and want to get feedback from thread followers: much of what is posted here is research news. But some things that I post fall more into the category of healthcare related news. Does it go here or should we have a separate thread? Thanks for sharing your thoughts. And also for your consistent, generous encouragement.
0 -
Clinical Challenges: Lymphedema in Breast Cancer
Risks have been reduced, but condition remains problematic
Article discusses standards of care, "prehabilitation" -- that is, maximizing patients' physical functioning prior to treatment; efforts toward education "about the procedure they are undergoing, as well as lymphedema risk reduction principles"; non-treatment risk factors; diagnosed and treated in a timely manner. "And that's important because chronic lymphedema is thought to be a condition that can be irreversible and lead to quality of life altering changes like infections and hospitalization, and other morbidities."
There are links to "results of an interim analysis of the PREVENT trial, a randomized trial evaluating bioimpedance spectroscopy versus tape measurement in the prevention of lymphedema following treatment for breast cancer."
0 -
Lumpie - in response to your question, I would not like a separate thread. I think the research news & health care news you post here are both appropriate. I like that there is a place to come get information without lots of discussion about personal issues.
0 -
This is a great thread. No need to separate the issues. Please continue as is. I am very grateful that you take the time.
0 -
Lumpie, regarding the thread, please Keep On Doin’ Whatcher Doin’
0 -
Lumpie- i agree, keep together.Thank you
0 -
YIP... keep this tread going Lumpie
0 -
agree, together is better
0 -
Moi aussi. General health news/research is interesting to all of us.
0 -
thank you lumpie
0 -
Lumpie
Thanks for posting he two articles.
Between the Stanford oncologist suggesting that giving false hope by suggesting treatment for recurrent breast cancer is like treating a chronic disease, and now this doc who is sort of saying the same thing when accessing past performance for survival prediction is like looking into a crystal ball.
Being recently diagnosed where are we really in predicting our future? Do we have a “day by day promise", “month to month luck" or just a plain “crap shoot" for survival with one median outcome for success - you and how you handle all these drugs?
Both oncologist seem to be saying past stats are like leaves blowing in the wind hard to know what tree they came from, hard to know where they will land with central tendency of no value. May be opinion - but very discouraging read.
My MO subscribes to a long survival cure-who to believe-a question now in my mind.
0 -
Hi Lumpie,
Love this thread, and come here often to catch up with what is new in research and healthcare. I think that is what makes it different to other threads - it is News rather than specific topic content. I have noticed that if you think content is relevant to other threads, you will post it there too.
I hope you keep the two together and share your discoveries with us here.
Cheers,
Jackie
0 -
I like it all in one place Lumpie, plus there is no other place to post related healthcare news. And when BCO posts a study we are not allowed to discuss it at their threads. I like that we can make comment here. You know as long as we don’t start talking about puppies and tights
0 -
I vote to have one common thread too but if puppies somehow landed here on occasion, I wouldn’t mind 😀🐶
0 -
Lumpie I vote to continue the thread as you have been doing it. It is so informative and I thank you so much for all your efforts!
Illimae once again you made me crack up!
0 -
YIP Lumpie.. you rock with this and we very much appreciate it
0 -
Thanks SO much, everyone, for your input. Everyone seems to be in favor of keeping things in one place - which sounds good to me. I have a couple of additions to post. Thanks again!!!
0 -
The Worst Patients in the World
Americans are hypochondriacs, yet we skip our checkups. We demand drugs we don't need, and fail to take the ones we do. No wonder the U.S. leads the world in health spending.
{Present company excepted, I am sure! But it's an interesting perspective.}
0 -
Never Say 'Die': Why So Many Doctors Won't Break Bad News
After nearly 40 years as an internist, Dr. Ron Naito knew what the sky-high results of his blood test meant. And it wasn't good.
But when he turned to his doctors last summer to confirm the dire diagnosis — stage 4 pancreatic cancer — he learned the news in a way no patient should.
The botched delivery of his grim diagnosis left Naito determined to share one final lesson with future physicians: Be careful how you tell patients they're dying.
https://khn.org/news/never-say-die-why-so-many-doctors-wont-break-bad-news/
This story also picked up/reported by NBC:
https://www.nbcnews.com/health/health-news/never-say-die-why-so-many-doctors-won-t-break-n1016876
{"Bless their hearts"... my doctors take turns giving me bad news. I know it's not fun... and I know that they don't have crystal balls. But as a patient, I need a raod map, even we don't know how fast we're going.}
0 -
ASCO 2019: KRISTINE Suggests Role for Chemotherapy-Sparing Regimen in HER2-Positive Breast Cancer
Combining trastuzumab-emtansine (T-DM1) with pertuzumab may be an effective chemotherapy-sparing regimen for some women with operable HER2-positive breast cancer, but identifying which women are good candidates for this approach and which would fare better with chemotherapy remains a challenge, according to the results of the KRISTINE trial presented here at the Annual Meeting of the American Society of Clinical Oncology, which took place from May 31 to June 4 (2019).
https://www.practiceupdate.com/C/85097/56?elsca1=emc_enews_topic-alert
---------------------------------------------------
Neoadjuvant Trastuzumab and Pertuzumab Plus Chemotherapy Versus T-DM1 and Pertuzumab in HER2+ Breast Cancer
- Interview with Lee S. Schwartzberg MD, FACP Interview by Farzanna S Haffizulla MD, FACP, FAMW
- https://www.practiceupdate.com/C/84837/56?elsca1=emc_enews_topic-alert
- {includes video}
0 -
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in HER2–Positive Breast Cancer
- Journal of Clinical Oncology PURPOSEThe KRISTINE study compared neoadjuvant trastuzumab emtansine plus pertuzumab (T-DM1+P) with docetaxel, carboplatin, trastuzumab plus P (TCH+P) for the treatment human epidermal growth factor receptor 2–positive stage II to III breast cancer. T-DM1+P led to a lower pathologic complete response rate (44.4% v55.7%; P = .016), but fewer grade 3 or greater and serious adverse events (AEs). Here, we present 3-year outcomes from KRISTINE.CONCLUSION
Compared with TCH+P, T-DM1+P resulted in a higher risk of an EFS event-free survival events owing to locoregional progression events before surgery, a similar risk of an IDFS event, fewer grade 3 or greater AEs during neoadjuvant treatment, and more AEs leading to treatment discontinuation during adjuvant treatment.
DOI: 10.1200/JCO.19.00882 Journal of Clinical Oncology0 -
6 Months vs 12 Months of Adjuvant Trastuzumab in Early Breast Cancer
- The Lancet This final report from a phase III trial provides data from patients with HER2-positive early breast cancer who were given 6 months versus 12 months of adjuvant trastuzumab. Therapy with 6 months of trastuzumab was not found to be noninferior to 12 months in this study.This study supports 12 months of trastuzumab as standard of care.
0 -
Compassion fatigue hits not only professional caregivers. Other people get it, too.
Vicki tried to lighten the load of a friend who was facing a terminal illness. "As she got sicker, I tried to relieve every burden I could imagine," ...She did this while also caring for her parents throughout their illnesses and deaths. ...her contemporaries continue to face dreaded diagnoses, with many needing assistance. Finally, she rightfully asked herself, "How much more could I do without getting even more tired and sad?"
{Article discusses compassion fatigue among caregivers.}
{Washington Post allows a limited number of views per month without subscription.}
0 -
The Business of Health Care Depends on Exploiting Doctors and Nurses
One resource seems infinite and free: the professionalism of caregivers.
{Opinion piece. A chilling and persuasive account of how the system - the business of healthcare - relies on physicians and nurses being rushed and doing work on uncompensated time - and how electronic medical records and administrative bloat exacerbate this problem.}
"The health care system needs to be restructured to reflect the realities of patient care. From 1975 to 2010, the number of health care administrators increased 3,200 percent. There are now roughly 10 administrators for every doctor..... Counting on nurses and doctors to suck it up because you know they won't walk away from their patients is not just bad strategy. It's bad medicine."
https://www.nytimes.com/2019/06/08/opinion/sunday/hospitals-doctors-nurses-burnout.html
{The New York Times allows a limited number of views per month without subscription.}
0 -
Success of breast cancer candidate spurs interest in ADCs
The late-stage testing success of the antibody drug conjugate DS-8201 for breast cancer has spurred increased interest in developing ADCs for what some analysts say could be treatments that replace chemotherapy. Some 56 drug companies are working on ADC candidates, and the ADC market is expected to hit nearly $10 billion by 2025.The Economic Times (India)/Bloomberg (6/14)
{I think that there was discussion above about ES's with this therapy. I think that this is actually the same article referenced in one of the posts above.}
0 -
Ultrasound, laser device detects and destroys circulating cancer cells
University of Arkansas for Medical Sciences researchers developed a device that uses ultrasound to detect circulating cancer cells and a laser to destroy the cells. An ultrasound transducer applied to the skin surface is able to detect sounds emitted by the cancer cells as they are heated by the laser, which then further heats them to kill them, the researchers report in Science Translational Medicine.New Atlas (6/17)
https://newatlas.com/cancer-cells-laser-ultrasound-detection-and-treatment/60158/
0 -
CMS drafts rule to improve e-prescribing, prior authorizations
The CMS released a proposed rule that would update the electronic prescribing standards and prior authorization process for Medicare Part D. The proposed changes "would reduce the time it takes for a patient to receive needed medications and ease the prescriber burden by giving clinicians the flexibility and choice to complete prior authorization transactions electronically," CMS Administrator Seema Verma said.Becker's Hospital Review (6/17),Health Data Management (free registration) (6/17)
0
